Akero Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of nonalcoholic steatohepatitis (NASH), a significant liver disease linked to cardiometabolic health. With its headquarters in South San Francisco, California, Akero is leveraging its proprietary drug development platform to restore metabolic balance and enhance patient outcomes. The company is at the forefront of advancing solutions that address the evolving needs of patients suffering from metabolic disorders.
Click "Analyze" to generate stock analysis
AKRO Price Trend and Signals
AKRO Option Volumes & Open Interests (aggregated)
AKRO Put Call Ratios and IV (aggregated)
AKRO Financials
2025-10-29Somewhat Bearishmacd_signal
Dead cross above zero detected.
2025-10-09Neutralvolume_signal
Abnormal volume detected compared to 5-day moving average.
2025-10-09Neutralvolume_signal
Abnormal volume detected compared to 10-day moving average.
2025-10-09Neutralvolume_signal
Abnormal volume detected compared to 20-day moving average.
2025-10-09Neutralvolume_signal
Abnormal volume detected compared to 3 mon moving average.